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Abstract
Background
Pyrazinamide (PZA) is crucial for tuberculosis (TB) treatment, given its unique ability to eradi-
cate persister bacilli. The worldwide burden of PZA resistance remains poorly described.
Methods
Systematic PubMed, Science Direct and Scopus searches for articles reporting phenotypic
(liquid culture drug susceptibility testing or pyrazinamidase activity assays) and/or geno-
typic (polymerase chain reaction or DNA sequencing) PZA resistance. Global and regional
summary estimates were obtained from random-effects meta-analysis, stratified by pres-
ence or risk of multidrug resistant TB (MDR-TB). Regional summary estimates were com-
bined with regional WHO TB incidence estimates to determine the annual burden of PZA
resistance. Information on single nucleotide polymorphisms (SNPs) in the pncA gene was
aggregated to obtain a global summary.
Results
Pooled PZA resistance prevalence estimate was 16.2% (95% CI 11.2-21.2) among all TB
cases, 41.3% (29.0-53.7) among patients at high MDR-TB risk, and 60.5% (52.3-68.6)
among MDR-TB cases. The estimated global burden is 1.4 million new PZA resistant TB
cases annually, about 270,000 in MDR-TB patients. Among 1,815 phenotypically resistant
isolates, 608 unique SNPs occurred at 397 distinct positions throughout the pncA gene.
Interpretation
PZA resistance is ubiquitous, with an estimated one in six incident TB cases and more than
half of all MDR-TB cases resistant to PZA globally. The diversity of SNPs across the pncA
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Introduction
The global burden of tuberculosis (TB) remains a major concern for health authorities world-
wide. In 2013, there were an estimated 9.0 million new cases and 1.5 million deaths from TB
[1]. Treatment regimens for drug-susceptible TB consist of rifampicin (RIF), isoniazid (INH),
pyrazinamide (PZA) and ethambutol (EMB). PZA forms a critical cornerstone of this regimen
given its unique ability to eradicate persister bacilli, which allowed treatment shortening from
9–12 months to 6 months [2,3]. PZA will likely remain an important component of treatment
regimens for drug-susceptible and multidrug-resistant TB (MDR-TB) because of its distinctive
mode of action (interference with ATP production) [4,5] and its synergistic pharmacokinetic
properties with two of the new anti-TB drugs: the diarylquinoline Bedaquiline (affects F1F0
proton ATP synthase) and the nitroimidazole PA-824 (enhances PZA activity by altering the
cell wall integrity) [6–12].
PZase is only active at low pH (pH 5.00–6.00) as experienced in the phagosomal compart-
ment. Down-regulation of efflux pumps in the persisterMycobacterium tuberculosis results
in intracellular accumulation of POA, which leads to the depletion of membrane potential
[13–17], and inhibits trans-translation [5]. The decreasing membrane potential is detrimental
to non-replicating persisters whose energy requirements are finely balanced [9]. Trans-
translation plays a role for stress survival and pathogenesis as it aids the management of stalled
ribosomes, damaged mRNA and proteins during stressful conditions [14, 18–20].
Even though PZA is a crucial component of TB treatment, little is known about the preva-
lence of PZA resistance, particularly on a global scale. PZA drug susceptibility testing (DST) is
technically challenging and rarely performed as part of routine care or routine drug surveil-
lance in resource-limited settings. Two phenotypic PZA DSTs, BACTEC 460TB and BACTEC
MGIT 960 (Becton Dickinson, Sparks, MD) exist; only BACTEC MGIT 960 is currently com-
mercially available. Neither of these assays has been approved by the World Health Organiza-
tion (WHO), likely due to their complexity and inconsistency, with frequent false positive
results [21,22]. Classic and modified Wayne’s PZase methods, which assess the function of the
PZase enzyme based on a colorimetric change at critical concentrations of 100μg/ml to 400μg/
ml, respectively [23], are also not endorsed by the WHO. More recently, genotypic PZA assays
have been developed based on observations that mutations in the pncA gene are the primary
mechanism of PZA resistance [15,24–27]. The pncA gene encodes the pyrazinamidase (PZase)
enzyme, which converts PZA, a pro-drug, into the active pyrazinoic acid (POA) [14,24]. These
molecular techniques, albeit not approved by WHO, are the most commonly used techniques
in PZA drug resistance studies.
Understanding regional differences in PZA resistance and its causal mutations is important
for policy decisions regarding treatment regimens for drug-resistant TB and development of
sequence-based diagnostics [26]. The aims of this review were to summarize the prevalence of
PZA resistance globally and by WHO geographic regions, and to estimate the annual burden
of PZA resistance, both stratified by MDR-TB status. We also summarize the global frequency
and distribution of single nucleotide polymorphisms (SNPs) in the pncA gene in PZA resistant
isolates.
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Materials and Methods
Search Strategy and Selection Criteria
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.[28] We searched PubMed, ScienceDirect and Scopus on July 14, 2014
for relevant articles published in the English language between 1998 and 2014 using an a priori
protocol. The search terms “tuberculosis AND (pyrazinamide OR PZA) AND (phenotype OR
genotype OR PZase OR pyrazinamidase OR pncAOR BACTEC OR mutations OR resistance
OR resistant OR susceptibility OR sequence analysis OR microbial sensitivity tests OR molecu-
lar typing)” were used to identify articles reporting on PZA resistance using any of the methods
of interest: phenotypic PZA DST, PZase activity assays, and/or genotypic PZA assays. Addi-
tional articles were identified from reference lists and review articles.
Studies were eligible for inclusion in the meta-analysis of prevalence of PZA resistance if (1)
PZA DST was assessed using at least one the following phenotypic tests: BACTEC liquid-based
DST 460 or 960, considered the reference standard for PZA DST, or PZase activity assays using
classic or modified Wayne’s methods [24]. If both BACTEC 960 and BACTEC 460 results
were reported, only the BACTEC 960 results were included. BACTEC 960 results were pre-
ferred to the BACTEC 460 due to the BACTEC 460 no longer being commercially available. If
results from BACTEC 460 using both a PZA concentration of 100μg/mL and 50μg/mL were
reported, the results using 100μg/mL were included. If results from both classical and modified
Wayne’s PZase assays were reported, the classical Wayne’s results were included. Authors were
contacted if no clear method of PZA DST is described in the article. To be eligible for inclusion
in the analysis, studies had to provide information on the MDR-TB risk status (patients diag-
nosed with MDR-TB, patients at high-risk of MDR-TB, or inclusion of any TB case), reporting
on a single subgroup or stratifying results by subgroup. High-risk of MDR-TB was defined as
an isolate being resistant to at least one anti-TB drug. Any TB was defined as the inclusion of
patients independent of drug resistance profile.
Studies were eligible for inclusion in the descriptive SNP analysis if they performed geno-
typic testing using polymerase chain reaction (PCR) and DNA sequencing and characterized
the found SNPs.
For both the PZA prevalence and pncA SNP analysis, studies including samples from multi-
ple countries were only included if the results were stratified by country. In studies collecting
multiple samples from a single patient, only the first sample result was used. Where a study
performed repeat testing on a sample, only the first result was retained in the review. No addi-
tional exclusion criteria were imposed.
Data Extraction
MGW and RMW independently reviewed titles and abstracts of original studies retrieved by
the search. MGW and TY reviewed full-text and references of selected articles. MGW and
HMS abstracted study data from full reports.
The following information, if available, was abstracted from each article: first author sur-
name; publication year; WHO region (Africa, Americas, Eastern Mediterranean, Europe,
South East Asia, or Western Pacific); study dates; study design; study setting; sample size;
MDR risk subgroup; age; gender; HIV status; exclusion criteria; specimen type; phenotypic
DST method; PZase activity assay; genotypic method; and whether the up and down stream
regions of pncA were sequenced. The number of patients with PZA resistance according to liq-
uid DST, the lack of PZase activity, or genotypic mutations in the pncA gene was also recorded.
As Taiwan was not defined by the WHO, it was grouped in the Western Pacific region.
Global Pyrazinamide Resistance
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Statistical Analysis
Summary estimates for the prevalence of PZA resistance, calculated using random-effects
meta-analytic methods in STATA 13 (StataCorp LP, College Station, TX), were determined
globally and for each WHO region, stratified according to whether the subgroup of patients
had MDR-TB, were at high-risk of MDR-TB, or had any TB.
Estimation of the burden of PZA resistant TB, stratified by region and by presence of
MDR-TB were obtained by multiplying the regional point estimates obtained by the random-
effects meta-analysis by the most recent (2011) regional WHO estimates for incident TB and
MDR-TB cases [1].
The analysis of SNPs in the pncA gene was descriptive. We present results according to
nucleotide position in order to identify regions of SNP clustering within the pncA gene. In
addition, we present a detailed description of all SNPs reported, including the location and
type of polymorphism and countries where this SNP has been isolated, as well as whether this
SNPs has been linked to a resistant phenotype only or has been observed in both resistant and
susceptible isolates, with phenotypic resistance defined by BACTEC DST results or the PZase
enzyme assay results if BACTEC DST result was not available.
Role of the funding source: The funders of the study (NIH and NRF) had no role in study
design, data collection, data analysis, data interpretation, or writing of the report. The corre-
sponding author had full access to all data in the study and had final responsibility for the deci-
sion to submit for publication.
Results
Selected Studies
The literature search resulted in 1077 abstracts identified. Of these, 205 full-text articles were
selected for review. In total, 62 [29–90] articles met the eligibility criteria for reporting PZA
resistance, resulting in 91 datasets due to articles having isolates from multiple WHO regions
as well as isolates which met different cohort type criteria (Fig 1). Of the 205 full-text articles
reviewed, 66 [27,59–123] articles were eligible for inclusion in the analysis of SNP frequency
and distribution.
Phenotypic PZA Resistance: Study and Population Characteristics
The 62 [29–90] final studies provided phenotypic PZA resistance data on 35,950M. tuberculo-
sis clinical isolates. According to WHO regions, 8 [39,59,60,68,69,78] studies were from
Fig 1. Flow diagram describing article selection.
doi:10.1371/journal.pone.0133869.g001
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African region, 20 [29,30,38,40,41,43–47,59,70–72,79–83] from the Americas, 3 [31,48,80]
from the Eastern Mediterranean, 20 [32,33,49–54,59,61,62,84–86] from European, 17 [34–
36,47,55,56,59,63,73,80] from South East Asia, and 23 [37,42,57,58,64–67,74–77,80,86–90]
from the Western Pacific region (Fig 2). Most (53/91) [30,35,36,39–61,63,64,78–90] estimates
of PZA prevalence were provided for studies including any TB patient, independent of drug
resistance profile; 25 [29–37,42,59–67] studies reported PZA resistance among individuals
with confirmed MDR-TB, and 13 [33,34,38,68–77] estimates were available for individuals at
high-risk of MDR-TB. Study and population characteristics are displayed in S1 Table.
Phenotypic PZA Resistance: Regional and Pooled Prevalences and
Annual Burden
PZA resistance is prevalent across the entire globe and has been reported in all six WHO-
defined regions (Fig 3). The pooled summarized prevalence estimate of PZA resistance was
60.5% (95% CI 52.3–68.6%) in MDR-TB patients, 41.3% (95% CI 29.0–53.7%) in TB patients
at high-risk of MDR-TB, and 16.2% (95% CI 11.2–21.2%) in studies including any TB patient
irrespective of resistance profile. In all six WHO regions, the prevalence of PZA resistance was
two to six times higher in MDR-TB patients compared to the population of all TB patients.
PZA resistance prevalence among cases of MDR-TB ranged from 48.8% (95% CI 30.1–
67.5%) in the Western Pacific to 80.0% (95% CI 65.7–94.3%) in the Eastern Mediterranean, but
the latter estimate was based on a single study [31]. The estimated PZA prevalence among
those at high risk of MDR-TB varied greatly, from 24.0% (95% CI 9.9–38.1%) in the Western
Pacific region to 75.0% (95% CI 64.4–85.6%) in South East Asian region. In the general TB
population, PZA prevalence estimated ranged from 11.4% (95% CI 1.6–21.2) in the European
region to 21.9% (95% CI 12.0–31.9%) in the Americas.
Multiplying the regional WHO estimates for the annual number of new TB cases and inci-
dent MDR-TB cases by the pooled summarized prevalence estimates of PZA resistance, we
estimated that about 1.4 million PZA resistant TB cases occur annually, corresponding to
16.2% of the 9.0 million incident TB cases in 2013 (Table 1). Of these, an estimated 270,000
occur in people also resistant to at least isoniazid and rifampicin, representing 60% of all inci-
dent cases of MDR-TB estimated in 2013.
Fig 2. Global distribution of included studies. Countries are shaded if a study was included in this review.
doi:10.1371/journal.pone.0133869.g002
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Single Nucleotide Polymorphism Distribution in pncAGene
The 66 [27,59–123] articles provided SNP data from 8,651M. tuberculosis clinical isolates.
According to WHO region, five [60,68,69,78,102] articles were from Africa, 14 [27,70–
72,79,81–83,97,100,105,107,114,120] from the Americas, two [80,92] from the Eastern Medi-
terranean, 17 [61,62,84–86,93,96,103,104,106,108–110,115–117,119] from Europe, six
[59,63,73,118,121,123] from South East Asia, and 22 [64–67,74–77,87–91,94,95,98,99,101,111–
113,122] from the Western Pacific. A SNP in the pncA region was detected in the 1,815 of the
8,651 isolates, with 608 unique polymorphisms in 397 positions in the gene (S2 Table). SNPs
were found throughout the entire pncA gene and flanking region with no particular clustering
or hot spots (Fig 4). There are however, a few SNPs which were found to be more frequently
than others such as -11 and 195, but even the 20 most frequent SNPs only represented one
third of all isolates with phenotypic PZA resistance.
Fig 3. Forest plot for the summary estimates of pyrazinamide prevalence byWHO region and
presence or risk of MDR-TB. Abbreviations: CI, confidence interval; DST, drug susceptibility test; MDR-TB,
multi-drug resistant tuberculosis; N/A, not applicable; WHO, world health organization. MDR-TB was defined
as an isolate being resistant to RIF and INH. High risk of MDR-TB was defined as an isolate being resistant to
at least one anti-TB drug. *Any TB was defined as the inclusion of patients independent of drug resistance
profile.
doi:10.1371/journal.pone.0133869.g003
Table 1. Estimated annual burden of new PZA resistant tuberculosis cases, overall and amongMDR-TB patients, globally and byWHO region.
WHO region Incident TB cases* Incident PZA resistant cases Incident MDR-TB cases* Incident PZA resistant MDR-TB cases
African 2,600 000 416,000 78,000 45,800
Americas 280,000 44,800 8,400 4,468
Eastern Mediterranean 750,000 120,000 27,000 21,600
European 360,000 57,600 91,000 62,881
South East Asian 3,400 000 544,000 135,000 81,675
Western Paciﬁc 1,600 000 256,000 125,000 61,000
GLOBAL 9,000 000 1,438 000 464,400 277,424
Abbreviations: MDR-TB, multi-drug resistant tuberculosis; PZA, pyrazinamide; TB, tuberculosis; WHO, World Health Organization.
* Incidence of TB cases from the World Health Organization Global Tuberculosis Report 2014.
doi:10.1371/journal.pone.0133869.t001
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Discussion
M. tuberculosis resistance to rifampicin and isoniazid is well described and monitored, either
through continuous surveillance or periodic surveys of a representative sample of patients
[124]. In contrast, resistance to ethambutol and PZA, the other two front line drugs, is not rou-
tinely monitored and thus poorly described. In this systematic review and meta-analysis, we
found that PZA resistance is ubiquitous and increases in prevalence as risk of resistance to
other drugs increases, with pooled summary estimates for the prevalence of PZA resistance of
16.2% in the total population of TB patients, 41.3% among TB patients at high risk of
MDR-TB, and 60.5% in patients with confirmed MDR-TB. The high prevalence of PZA resis-
tance results in an annual estimated burden of 1.4 million new cases of PZA resistant TB, of
which about 270,000 occur in patients with MDR-TB [1]. This high prevalence of PZA resis-
tance observed in all regions of the world and across different TB patient groups is an impor-
tant finding as PZA is not only a key component of all current regimens for both drug
susceptible and drug resistant TB but is also included in all novel drug regimens currently
undergoing evaluation in clinical phase II or III trials for treatment of drug-susceptible or
drug-resistant TB [125].
While our review aimed to comprehensively summarize information on PZA as a global
public health problem, a different systematic review by Chang et al aimed to summarize the
performance of molecular and PZase assays compared to culture-based phenotypic DST [126].
In that review, the median (range) of PZA resistance was 5% (0% to 9%) in non-MDR isolates
and 51% (31% to 89%) in MDRM. tuberculosis isolates [126]. Our pooled prevalence estimates
were higher than the median prevalence reported by Chang et al., especially in the overall TB
patient population (16.2%). The summary estimate in our review may have overestimated the
overall prevalence of PZA resistance among TB patients if the proportion of patients with drug
resistance included in the studies was higher than that observed in the general population of
the country where the studies took place.
The high prevalence of PZA resistance and its inclusion in both standard and novel drug
regimens highlights the need for routine PZA resistance testing. Others have suggested that
molecular assays may be the way forward for detecting PZA resistance, based on findings that
molecular assays targeting pncA can detect PZA resistance in MDR-TB isolates with high posi-
tive predictive values and rule out PZA resistance in non-MDR isolates with high negative pre-
dictive values [126,127]. However, DNA sequencing studies have revealed that mutations and/
or polymorphisms occur across the entire length of the pncA gene, suggesting that sequencing
the entire pncA gene would be essential to capture all possible mutations [109,117,127–129]. In
this review, we confirmed that on a global scale, SNPs are distributed throughout the entire
Fig 4. Distribution of reported single nucleotide polymorphisms (SNPs) throughout the pncA gene.
Dashed lines indicate the open reading frame for the pncA gene.
doi:10.1371/journal.pone.0133869.g004
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pncA gene. Whereas the tbdream database [14,26] previously reported on 278 unique polymor-
phisms prior to 2009, our systematic review provides an updated overview, with information
on more than 600 unique polymorphisms in approximately 400 positions in pncA (including
the upstream flanking region). A few SNPs occurred more frequently than others, possibly
because these SNPs are rooted in ancestral strains. Consequently, developing a molecular assay
to detect PZA resistance will be much more challenging compared to other genes (rpoB, gyrA,
embB) which have been found to have clear resistance-causing hot spots [130]. The identifica-
tion of causal PZA mutations is further complicated by the fact that not all non-synonymous
mutations cause phenotypic resistance [80] and that mutations in the pncA gene can be absent
in a small percentage of phenotypically PZA resistant isolates, [66,102] suggesting that PZA
resistance could be conferred via an alternative mechanisms such as mutations in the rpsA
gene [81]. Whereas development of simplified micro-array systems for simultaneous detection
of rifampicin, isoniazid and ethambutol resistance may be possible, [131] inclusion of assess-
ment of PZA resistance may thus require a different approach such as targeted DNA sequenc-
ing or next generation sequencing [127,132].
A major strength of our study was the comprehensive inclusion of studies from across the
globe and stratification of estimates by region and TB patient category. Insight into PZA preva-
lence by region and TB patient category provides essential information for the development
and clinical use of future PZA resistance tests. Our study adds to the review by Chang et al,
which was aimed at summarizing PZA resistance assay performance, not PZA resistance prev-
alence. Our review also complements the recent study by Miotto et al, which presented pncA
sequence results of 1950 clinical isolates obtained from multiple laboratories, but did not strat-
ify results by regions or MDR-TB status [127]. Our review was however limited by the data
quality of the original studies [126]. Misclassification of PZA resistance may have occurred in
the studies included, and due to false positive results, may have resulted in an overestimate of
the true prevalence of PZA resistance. Phenotypic PZA drug susceptibility testing has not been
endorsed by the WHO perhaps due to concerns surrounding false positivity related to the acid-
ity of the media, inoculum size and critical concentration used [17,133,134]. Alternative tech-
niques, the PZase activity assays, [23,135] have been used in the hope of identifying PZA
resistance more accurately, but the interpretation of colourmetric change for these assays is
highly subjective [56]. It is uncertain whether all mutations observed in the pncA region are
associated with resistance. Similar to the tbdream database approach, [26] we chose not to
make a priori decisions as to whether mutations described actually confer resistance and report
any mutation found in a PZA-resistant isolate. Another limitation was the restricted number
of studies for certain regions (especially Eastern Mediterranean, where all strains included
came from a single study in Pakistan) and the lack of adequate representation of countries
within certain regions (especially for Africa, where almost all isolates included came from
South Africa, and the Americas). This not only resulted in uncertainty of the accuracy of the
point estimates and wide confidence intervals but also highlights the lack of information on
PZA resistance in several regions of the world. Finally, many studies did not provide clinical
information and we were therefore unable to stratify our analysis by new versus re-treatment
status.
The ubiquitous presence of PZA resistance is of global interest and should signal a call to
action. Development of rapid diagnostics to detect PZA resistance will be essential to maximize
the efficacy of novel treatment regimens and minimize the risk of development of resistance to
novel drugs. In addition, the high prevalence of PZA resistance, especially among MDR-TB
patients, highlights the need for development of treatment regimens that can be effectively
used in patients with PZA-resistant MDR-TB.
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